Updated: J&J Will Pay At Least $400m For Laminar To Add Stroke-Stopping Technology

Currently available catheter-based devices for left-atrial appendage closure block the opening from the left atrium into the appendage, while Laminar’s innovative approach uses rotational motion to “eliminate” the LAA.

stroke
• Source: Shutterstock

[Editor's note: This article was updated on 1 December to include more comments from Wall Street analysts that were published late on 30 November.]

Johnson & Johnson Medtech/Biosense Webster is acquiring Laminar, the California-based developer of a novel transcatheter device that eliminates the left-atrial

On 30 November, J&J announced that it has completed a deal to buy Laminar for an upfront payment of $400m, plus “additional potential clinical and regulatory milestone payments” beginning in 2024

More from Deals

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By 

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

Anglonordic 25: Women’s Health Needs Therapeutic Success To Encourage Wider Investment

 

Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.

More from Business